Politics

Watch: Where Do Our Generic Drugs Come From? We Dug to Find Out.

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 09/11/2026, 17:24:25 UTC.

Briefings

A 14-month investigation by ProPublica revealed that the U.S. FDA allows generic drug imports from factories with documented safety violations, including mold, acid, and metal contamination. The agency exempted at least 150 drugs from banned factories over a dozen years, yet these drugs remain in the U.S. system. A specific case involving a 21-year-old transplant patient who died from tacrolimus toxicity highlights the risk of underdosing. The investigation found that inspection reports redact names of affected drugs, preventing public accountability. The authors also developed an online tool to track drug origins and inspection outcomes.

Key points

• The FDA has exempted at least 150 drugs or their ingredients from banned factories over a dozen years, despite inspectors reporting unsafe conditions like mold, acid, and metal contamination at these facilities.
• A transplant patient named Hannah Goetz died at age 21 after taking tacrolimus from two manufacturers with documented problems, raising concerns about underdosing and organ rejection risks.

Context

This report details a 14-month investigation by ProPublica into the U.S. generic drug system, focusing on the FDA's regulatory exemptions for unsafe factories. The investigation involved interviews with inspectors, lab testing, and legal action against the government. It highlights the gap between public safety concerns and the agency's ability to track affected medications.

Limitations

The investigation relies on interviews with factory inspectors and lab testing conducted by the authors. The FDA redacts names of drugs from inspection reports, preventing public accountability. The authors developed an online tool to track origins, but the data may be incomplete or outdated. The investigation covers a 14-month period and focuses on U.S. regulations, with limited context on international production.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 10/11/2026, 05:39:52 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeih237nknv5slazhuma5tghamkg2lf2zkj7qkafejkniyyu7isv6wq